Superiority ntawm Cystatin C dhau Creatinine Rau Kev Ntsuas Thaum Ntxov Ntawm Kev Mob Raum Mob Hauv Pediatric Acute Lymphoblastic Leukemia / Lymphoblastic Lymphoma

Hu rau: emily.li@wecistanche.com

Takashi Yamazoe, et al

Qhov tseeb tshwm sim ntawmmob raum mob (AKI)Thaum lub sij hawm kws khomob rau mob lymphoblastic leukemia (TAG NRHO) / ​​lymphoblastic lymphoma (LBL) tsis paub. Tsis tas li ntawd, cov neeg mob qog noj ntshav thaum yau muaj kev pheej hmoo ntawm AKI-chronicraumkab mobkev hloov pauv. Yog li, kev kuaj mob ntxov ntawm AKI yog qhov tseem ceeb. Txoj kev tshawb no tau tsom mus rau kev nthuav qhia qhov tshwm sim ntawm AKI hauv cov neeg mob uas tau txais tshuaj kho mob rau menyuam yaus ALL / LBL thiab los sib piv cov txiaj ntsig ntawm cov ntshav cystatin C (CysC)- thiab creatinine (Cr)-raws li kwv yees glomerular filtration rate (eGFR) raws li kev ntsuas ntsuas. Cov ntaub ntawv ntawm 16 tus neeg mob nrog ALL / LBL kho nrog tag nrho ntawm 75 chav kawm ntawm kws khomob tau raug tshuaj xyuas rov qab. CysC- thiab Cr-based eGFR tau ntsuas ua ntej thiab peb zaug hauv ib lub lis piam thaum kho. Txhawm rau xam eGFR, ib qho kev sib npaug rau cov menyuam yaus Nyij Pooj tau siv. AKI tau kuaj pom thaum eGFR poob qis dua los yog sib npaug li 25 feem pua ​​​​los ntawm qhov siab tshaj eGFR tus nqi tau txais nyob rau hauv 2 lub lis piam dhau los txij li pib siv tshuaj khomob. AKI tau muab qhab nia raws li kev pheej hmoo rau menyuam yaus, Kev raug mob, Kev Ua Tsis Taus, Poob, Qhov Kawg Lub Raum Kab Mob. Txhua tus neeg mob tsim AKI thaum siv tshuaj khomob; Txawm li cas los xij, ntau dua 90 feem pua ​​​​ntawm cov neeg mob tau mob me thiab thaum kawg rov zoo. Tsis muaj qhov sib txawv tseem ceeb hauv qhov tshwm sim ntawm AKI ntawm CysC- thiab Cr-based eGFR (p=0.104). Lub sijhawm nruab nrab ntawm AKI kuaj pom tau luv luv hauv CysC-based eGFR dua li hauv Cr-based eGFR (8 vs. 17 hnub, p < 0.001).="" hauv="" txoj="" kev="" tshawb="" no,="" txhua="" tus="" neeg="" mob="" uas="" muaj="" menyuam="" yaus="" all/lbl="" tuaj="" yeem="" tsim="" aki="" me="" me="" thaum="" kho.="" cysc-based="" egfr="" yog="" qhov="" ntsuas="" tau="" zoo="" dua="" li="" cr-based="" egfr="" rau="" kev="" kuaj="" mob="" ntxov="" ntawm="">

Ntsiab lus: mob raum raug mob;mob lymphoblastic leukemia; kws khomob; creatinine; cystatin C

Taw qhia

Mob raum mob (AKI)yog ib qho ntawm cov kab mob loj heev uas cuam tshuam nrog kev kho mob leukemia vim nws ua rau muaj kev tuag ntau ntxiv. Hauv cov neeg laus mob leukemia (mob myeloid leukemia thiab muaj kev pheej hmoo siab myelodysplastic syndrome), ib feem peb ntawm cov neeg mob uas tau txais kev khomob khomob tsim AKI, thiab cov neeg mob no pom tau tias muaj tsib npaug ntawm kev tuag (Lahoti li al. 2010). Txawm li cas los xij, nyob rau hauv cov neeg laus thiab menyuam yaus mob qog nqaij hlav qog ntshav qog ntshav (TXL), qhov tshwm sim ntawm AKI thaum siv tshuaj khomob tsis paub tshwj tsis yog rau cov neeg muaj feem cuam tshuam nrog cov qog lysis lossis cuam tshuam nrog cov tshuaj khomob tshwj xeeb xws li methotrexate (Perazella 1999), cisplatin (Pabla thiab Dong). 2008), thiab ifosfamide (Ciarimboli li al. 2011).

AKI yog ib qho kev pheej hmoo rau yav tom ntej txoj kev loj hlob ntawm kev mob ntevraumkab mob(CKD), ib qho mob uas tshwm sim los ntawm kev ua haujlwm tsis zoo ntawm lub raum. Raws li cov ntaub ntawv dhau los los ntawm Childhood Cancer Survivor Study, qhov tshwm sim ntawm CKD yog li ntawm 2.4 feem pua ​​​​mus rau 32 feem pua ​​​​ntawm cov neeg muaj mob qog noj ntshav thaum yau (Kooijmans et al. 2019). Yog li, kev kuaj mob ntxov thiab kev kho mob ntawm AKI thaum siv tshuaj kho mob rau TXHUA tus, uas tuaj yeem txo qhov kev pheej hmoo ntawm kev hloov pauv AKI-CKD, muaj qhov tseem ceeb hauv kev kho mob.

Txawm hais tias ntshav creatinine (Cr) yog dav siv rau kev kuaj mob ntawm AKI, nws raug cuam tshuam los ntawm ntau yam tsis yog.lub raummuaj nuj nqi, suav nrogpoj niam deev, hnub nyoog, thiab cov leeg nqaij (Kellum et al. 2013). Cystatin C (CysC), uas tsis cuam tshuam los ntawm cov ntsiab lus saum toj no (Laterza li al. 2002), tuaj yeem tsim nyog thiab rhiab rau kev soj ntsuam ntawm lub raum ua haujlwm hauv cov menyuam yaus (Lankisch li al. 2006; Nakhjavan-Shahraki et al. 2017).

Nyob rau hauv txoj kev tshawb no, peb tsom kom paub meej qhov tshwm sim ntawm AKI hauv menyuam yaus ALL / lymphoblastic lymphoma (LBL) thaum siv tshuaj khomob thiab sib piv cov txiaj ntsig ntawm CysC-based kwv yees glomerular filtration rate (eGFR) nrog Cr-based eGFR hauv kev kuaj mob. AKI thaum ALL/LBL kho.

Cistanche rau lub raum raug mob

Cov ntaub ntawv thiab cov txheej txheem

Kev pom zoo ntawm kev ncaj ncees thiab kev tso cai los koom

Tag nrho cov txheej txheem ua tiav hauv txoj kev tshawb fawb no tau ua raws li cov qauv kev coj ua ntawm pawg kws tshawb fawb hauv lub koom haum uas cov kev tshawb fawb tau ua (Kansai Medical University; tsis muaj. 2019288) thiab nrog 1964 Helsinki tshaj tawm thiab nws cov kev hloov kho tom qab lossis cov qauv kev coj ncaj ncees sib piv. Cov kws sau ntawv tsis tau ua qhov kev sim ntawm cov tsiaj hauv qhov kev tshawb fawb no.

Cov neeg tuaj koom thiab sau cov qauv

Kaum plaub TAG NRHO tus neeg mob thiab ob tus neeg mob LBL hnub nyoog 2-18 xyoo tau kho hauv Lub Tsev Haujlwm Saib Xyuas Menyuam Yaus ntawm Kansai Medical University Tsev Kho Mob txij Lub Ob Hlis 2016 txog Lub Xya Hli 2020 tau suav nrog. Tsis muaj cov neeg tuaj koom tau pom qhov nce siab Cr lossis CysC vim mob qog nqaij hlav lysis lossis blast infiltration ntawm kev kuaj mob. Cov neeg mob tau txais tag nrho ntawm 75 chav kawm ntawm kws khomob. Serum CysC thiab Cr qib tau raug ntsuas los xam eGFR (CysC-based eGFR thiab Cr-based eGFR, respec tively) (Uemura li al. 2014a, b), ua ntej thiab peb zaug hauv ib lub lis piam thaum txhua chav kawm ntawm kev kho mob. Muaj 14 chav kawm ntawm induction, 12 chav kawm ntawm kev sib sau ua ke thaum ntxov, 25 chav kawm ntawm kev sib koom ua ke, thiab 24 chav kawm ntawm kev rov ua dua tshiab (Table 1). Cov kws khomob no suav nrog cyclophosphamide, cytarabine, dasatinib, daunorubicin, doxorubicin, etoposide, ifosfamide, L-asparaginase, mercaptopurine, methotrexate, pirarubicin, vincristine, thiab vindesine. Cov neeg mob tau raug kho raws li Japanese Pediatric Leukemia / Lymphoma Study Group raws tu qauv.

Kev soj ntsuam ntawm AKI

AKI tau kuaj pom thaum eGFR poob los ntawm 25 feem pua ​​​​lossis ntau dua los ntawm qhov siab tshaj eGFR tus nqi tau txais nyob rau hauv 2 lub lis piam dhau los txij li pib siv tshuaj khomob. AKI tau muab qhab nia raws li kev pheej hmoo ntawm menyuam yaus, Kev raug mob, tsis ua haujlwm, poob, Lub Raum Kab Mob Kawg (pRIFLE) (Akcan-Arikan li al. 2007) raws li qhia hauv Table 2, txawm hais tias qhov txo qis hauv cov zis tso zis tsis tau siv rau hauv qhov no. kawm. AKI tau kuaj pom siv CysC- thiab Cr-based eGFR ntawm nws tus kheej, thiab kev kuaj mob tau muab piv rau AKI qhov xwm txheej, qhov hnyav, thiab hnub kom txog thaum AKI kuaj xyuas txij thaum pib ntawm txhua chav kho mob.

Ntev mus ntev

Txhawm rau soj ntsuam cov txiaj ntsig ntawm lub raum mus ntev xws li kev tsim kho ntawm CKD, CysC-based eGFR tau ua raws li lub Peb Hlis 2021 nrog rau kev kuaj zis thiab ntshav. CKD tau soj ntsuam feem ntau siv covLub raumKab mob: Txhim Kho Ntiaj Teb Cov Tau Txais (KDIGO) txhais: muaj tsawg eGFR (eGFR < 90 mL / min / 1.73 m2 ) lossis proteinuria (cov protein ntau dua lossis sib npaug 1 ntxiv los ntawm cov zis tso zis) (Kab mob raum: Txhim Kho Ntiaj Teb Cov Txheej Txheem (KDIGO) CKD Pawg Ua Haujlwm 2013)

Cov txheej txheem txheeb cais

Cov ntaub ntawv ntawm kev sib deev, hnub nyoog, hom leukemia, kev pheej hmoo, tus naj npawb ntawm cov chav kawm, kev kho mob ntau npaum li cas, thiab lub sijhawm tau muab rho tawm los ntawm cov ntaub ntawv kho mob. Rau kev txheeb xyuas cov ntaub ntawv, Mann– Whitney U test lossis chi-square test tau siv, thiab p < 0.05="" tau="" suav="" tias="" yog="" qhov="" tseem="" ceeb.="" txhawm="" rau="" txheeb="" xyuas="" cov="" txiaj="" ntsig,="" tom="" qab="" hoc="" zog="" tsom="" xam="" nrog="" qhov="" tseem="" ceeb="" ntawm="" qib="" 0.05="" tau="" ua="" tiav="" siv="" g="" *="" power="" version="" 3.1.9.4="" (heinrich-heine="" university,="" düsseldorf,="" germany)="" (faul="" et="" al.="">

Table 1. Tus neeg mob cov yam ntxwv thiab qhov tshwm sim ntawm mob hnyavraumraug mob(AKI)

Kuv, induction; EC, kev sib sau ua ke thaum ntxov; C, sib sau ua ke; R, rov induction; TAG NRHO, mob lymphoblastic leukemia; Ph, Philadelphia chromosome; AKI, mobraumraug mob; BMI, lub cev hnyav index; Cr, creatinine; CysC, cystatin C; IQR, interquartile ntau; LBL, lymphoblastic lymphoma. * Tus naj npawb ntawm AKI ntu kuaj pom los ntawm CysC-based eGFR; †Number of AKI ntu kuaj pom los ntawm Cr-based eGFR; ‡Number of AKI ntu kuaj pom los ntawm CysC-based eGFR thiab Cr-based eGFR.

Table 2. Pediatric Risk, Injury, Failure, Poob, End Stage Renal Disease scale (pRIFLE) classification

eGFR, kwv yees glomerular filtration rate. Hloov los ntawm "Akcan-Arikan, A., Zappitelli, M., Loftis, LL, Washburn, KK, Jefferson, LS & Goldstein, SL (2007) Hloov kho RIFLE cov qauv hauv cov me nyuam mob hnyav nrog mob hnyav.raumraug mob. Raum Int., 71, 1028-1035." nrog kev tso cai los ntawm International Society of Nephrology

Cov txiaj ntsig

Qhov xwm txheej thiab qhov hnyav ntawm AKI

Peb tau tshuaj xyuas 16 tus neeg tau txais tag nrho ntawm 75 chav kawm ntawm kws khomob. Ntawm cov no, 12 yog txiv neej thiab hnub nyoog nruab nrab yog 9.4 xyoo nrog qhov sib txawv (IQR) ntawm 7.2 txog 13.1 xyoo. Qhov nruab nrab qhov siab yog 132.5 cm (IQR, 117.8 txog 153.4 cm), thiab nruab nrab lub cev hnyav yog 28.7 kg (IQR, 19.1 txog 42.4 kg). Lub cev qhov hnyav yog 16.3 (IQR, 15.7 txog 18.4) kg / m2. Qhov nruab nrab Z-cov qhab nia rau qhov siab thiab qhov hnyav raws li Japanese cov qauv kev loj hlob (Isojima li al. 2{{30}}}16) yog −0.3 (IQR, −1.{36 } } rau 0.5) thiab −0.6 (IQR, −1.1 txog 0.3), raws li (Table 1).

Raws li qhia hauv Table 3, tag nrho 16 tus neeg mob tau tsim AKI thaum siv tshuaj khomob (100 feem pua ​​​​ntawm qhov tshwm sim) thiab nws thiaj li rov zoo. Thaum lub sijhawm 75 chav kawm, AKI tau kuaj pom hauv 58 chav kawm los ntawm CysC-based eGFR (77 feem pua ​​​​: "Risk" 72 feem pua ​​, "Injury" 4.0 feem pua ​​, "Failure" 1.3 feem pua ​​, "Loss" 0 feem pua) thiab hauv 49 chav kawm los ntawm Cr-based eGFR (65 feem pua ​​​​: "Risk" 61 feem pua ​​​​, "Kev raug mob" 2.7 feem pua, "Failure" 1.3 feem pua, "Poob" 0 feem pua). AKI tau kuaj pom hauv 42 chav kawm los ntawm CysC-raws li eGFR thiab Cr-based eGFR (56 feem pua) txawm tias tsis muaj tus mob qog lysis thaum siv tshuaj khomob.

Txij li thaum glucocorticoids tuaj yeem cuam tshuam rau cov ntshav CysC qib (Bardi li al. 2010; Nakamura li al. 2018; Cimerman li al. 2000), qhov tshwm sim ntawm AKI raws li CysC-based eGFR tau muab piv rau cov xwm txheej kho glucocorticoid. Tsis muaj qhov sib txawv tseem ceeb hauv qhov tshwm sim ntawm AKI: 77.4 feem pua ​​​​thaum siv tshuaj khomob nrog glucocorticoids thiab 77.3 feem pua ​​​​thaum siv tshuaj khomob yam tsis muaj glucocorticoids. Qhov tshwm sim ntawm AKI los ntawm hom kev siv tshuaj khomob yog qhia hauv Table 4. AKI tau tshwm sim ntau zaus hauv cov chav kawm sib sau uas suav nrog methotrexate. AKI tau kuaj pom hauv 24 ntawm 25 chav kawm sib koom ua ke (96 feem pua) raws li CysC-based eGFR thiab 22 ntawm 25 chav kawm sib koom ua ke (88 feem pua) raws li Cr-based eGFR (Table 4).

Qhov tsis sib xws tau pom nyob rau hauv 23 chav kawm hais txog qhov tshwm sim ntawm AKI kuaj pom los ntawm CysC-based eGFR thiab Cr-based eGFR: 7 chav kawm tau kuaj pom tias muaj AKI nkaus xwb los ntawm Cr-based eGFR, thaum 16 chav kawm tau kuaj pom tias muaj AKI nkaus xwb los ntawm CysC- raws li eGFR (Table 3). Txawm li cas los xij, tsis muaj qhov sib txawv tseem ceeb hauv qhov tshwm sim ntawm AKI tsis hais seb CysC-based eGFR lossis Cr-based eGFR tau siv rau kev kuaj mob (p=0.104).

Hnub mus txog qhov pib ntawm AKI

Ntxiv mus, rau 42 chav kawm uas AKI tau kuaj pom los ntawm ob qho tib si CysC- thiab Cr-based eGFR, peb piv cov hnub txij li pib ntawm txhua chav kho mob rau AKI kuaj mob. Lub sijhawm nruab nrab ntawm AKI kev kuaj mob yog qhov luv luv rau CysC-based eGFR (8 hnub [IQR, 4 txog 21 hnub]) dua li rau Cr-based eGFR (17 hnub [IQR, 10 txog 31 hnub], p <0.001) (fig.="" 1).="" ntawm="" 42="" chav="" kawm="" uas="" aki="" tau="" tsim,="" muaj="" cov="" kev="" hloov="" pauv="" hauv="" qhov="" txo="" qis="" ntawm="" cysc-="" thiab="" cr-based="" egfr="" nyob="" rau="" 2="" lub="" lis="" piam="" txij="" li="" pib="" siv="" tshuaj="" khomob="" (fig.="" 2).="" cysc-raws="" li="" egfr="" tau="" pom="" qhov="" poob="" qis="" dua="" li="" cr-based="">

Kev taug qab mus ntev

Ntawm 16 tus neeg mob, 13 tau ua raws li lub Peb Hlis 2021. Peb tus neeg mob tau ploj mus tom qab lawv tsiv mus rau qhov chaw deb. Lub sijhawm ua raws li kev kho mob rov qab siv dua li ntawm 18 txog 57 lub hlis (qhov nruab nrab, 29 lub hlis; IQR, 18-45 hli). Tsis muaj cov neeg mob uas muaj proteinuria tseem ceeb lossis muaj CysC-based eGFR < 90="" ml="" min="">

Cistanche rau lub raum ua haujlwm

Post hoc zog tsom xam

Kev txheeb xyuas lub zog tom qab lub zog tau ua tiav siv G*Power 3.1.9.4 (Heinrich-Heine University, Düsseldorf, Lub Tebchaws Yelemees) los soj ntsuam cov txiaj ntsig tseem ceeb ntawm lub sijhawm rau kev kuaj mob AKI (Faul et al. 200 7). Cov nyhuv loj ntawm peb cov ntaub ntawv yog {{10}}.609. Thaum qhov tseem ceeb theem tau teem rau 0.05, lub zog yog 0.855, uas yog ntau dua 0.80. Yog li, qhov kev tshuaj xyuas tau lees paub tias tus qauv loj txaus rau kev txheeb xyuas kev txheeb xyuas (Cohen 1992).

Table 3. Kev mob tshwm simraumraug mob(AKI) nyob rau hauv cov chav kawm ntawm chemotherapy nyob rau hauv cov me nyuam mob mob lymphoblastic leukemia / lymphoblastic lymphoma (ALL / LBL)

AKI, mobraumraug mob; CysC, cystatin C; Cr, creatinine; eGFR, kwv yees glomerular pom tus nqi; ESRD, kab mob raum kawg.

Table 4. Kev mob tshwm simraumraug mob(AKI) los ntawm hom kev siv tshuaj khomob thiab kev tswjfwm hauv menyuam yaus mob qog noj ntshav qog ntshav ntshav / lymphoblastic lymphoma (ALL / LBL).

AKI, mobraumraug mob; CysC, cystatin C; Cr, creatinine; eGFR, kwv yees glomerular pom tus nqi; ESRD, kab mob raum kawg.

Fig. 1. Sib piv cov hnub txij li pib siv tshuaj kho mob mus rau qhov mob raum raug mob (AKI). Cov hnub nruab nrab rau AKI ( Tsawg dua lossis sib npaug li 25 feem pua ​​​​ntawm kev txo qis hauv CysC-based eGFR) yog 8 hnub (interquartile range, 4 txog 21 hnub), piv nrog 17 hnub (interquartile range, 10 mus txog 31 hnub) hauv Cr-based eGFR (p <0.001). cov="" kab="" kab="" rov="" tav="" nyob="" rau="" hauv="" lub="" thawv="" sawv="" cev="" rau="" qhov="" nruab="" nrab="" qhov="" tseem="" ceeb,="" thiab="" hauv="" qab="" thiab="" sab="" saum="" toj="" ntawm="" lub="" thawv="" sawv="" cev="" rau="" 25th="" thiab="" 75th="" feem="" pua,="" feem.="" cov="" kab="" ntsug="" txuas="" ntxiv="" los="" ntawm="" lub="" thawv="" rau="" 5="" thiab="" 95="" feem="" pua.="">mob raum raug mob; Cr, creatinine; CysC, cystatin C; eGFR, kwv yees glomerular filtration rate.

Kev Sib Tham Peb txoj kev tshawb fawb tau qhia tias txhua tus neeg mob tau ntsib AKI tsawg kawg ib zaug thaum ALL / LBL kev kho mob thiab AKI tau kuaj pom hauv 77 feem pua ​​​​ntawm tag nrho cov kev kho mob uas siv CysC-based eGFR. Ib txoj kev tshawb fawb qhia txog qhov tshwm sim ntawm 16.2 feem pua ​​​​hauv ib pawg ntawm 831 tus neeg mob tau txais tshuaj kho mob rau cov menyuam yaus mob ntshav qab zib mellitus (Fisher li al. 2010). Lwm daim ntawv tshaj tawm qhia pom tias muaj 39 feem pua ​​​​ntawm AKI hauv kev tshawb fawb ntawm 23 tus menyuam yaus uas muaj qog nqaij hlav (McMahon li al. 2018). Rau peb txoj kev paub, tsis muaj kev tshawb fawb tau soj ntsuam qhov tshwm sim ntawm AKI ntawm cov neeg mob ALL / LBL. Hauv txoj kev tshawb fawb tam sim no, qhov tshwm sim ntawm AKI thaum siv tshuaj khomob yuav siab dua qhov kev cia siab ntawm cov kws kho mob oncologist lossis lwm yam kev tshwm sim yav dhau los hauv cov neeg mob qog noj ntshav. Qhov tsis sib xws ntawm qhov tshwm sim ntawm AKI tuaj yeem piav qhia los ntawm ntau qhov laj thawj. Ua ntej, kev ntsuam xyuas ntau zaus ntawm lub raum ua haujlwm raws li cov lus qhia ntawm cov kws kho mob nephrologists, kuaj ntshav tsawg kawg 3 zaug hauv ib lub lis piam, ua rau muaj kev saib xyuas ntau dua, thiab peb tuaj yeem kuaj tau txawm tias mob AKI. Qhov thib ob, qhov sib txawv cri teria tau siv hauv kev tshawb fawb yav dhau los. Rau kev kuaj mob ntawm AKI, qee qhov kev tshawb fawb tau siv cov kab mob hauv lub raum: Txhim kho Cov Txheej Txheem Thoob Ntiaj Teb (Sutherland et al. 2015; Meersch et al. 2017) lossis cov qauv pRIFLE (Sethi li al. 2015; Sutherland et al. 2015), thaum. lwm tus tau siv International Statistical Classification of Diseases and Related Health Problems codes (Ko et al. 2018). Thib peb, cov tshuaj siv hauv cov txheej txheem sib txawv tuaj yeem cuam tshuam cov txiaj ntsig. Plaub, Cr-based eGFR tau siv los ntsuas lub raum ua haujlwm hauv kev tshawb fawb feem ntau (McMahon li al. 2018), thiab CysC-based eGFR tsis tshua siv (Yong et al. 2017; Nakamura li al. 2018).

Kev txhim kho hauv kev kuaj mob thiab kev kho mob ntawm cov neeg mob qog noj ntshav hauv menyuam yaus tau ua rau muaj cov neeg mob qog noj ntshav nce ntxiv. Txawm li cas los xij, ntau tus neeg mob qog noj ntshav thaum yau muaj teeb meem kev noj qab haus huv ntau xyoo tom qab vim lawv txoj kev kho mob qog noj ntshav. Koojmans et al. (2019) tau tshuaj xyuas cov kev tshawb fawb yav dhau los ntawm lub raum tsis ua haujlwm hauv cov menyuam yaus uas muaj mob qog noj ntshav. Lawv tau tshaj tawm tias feem ntau ntawm CKD yog li ntawm 2.4 feem pua ​​​​rau 32 feem pua. Lwm txoj kev tshawb fawb tau tshaj tawm tias 0.5 feem pua ​​​​ntawm ntau dua 10,000 cov neeg mob qog noj ntshav thaum yau tau kho thaum xyoo 1970 thiab 1980s tau tsim lub raum tsis ua haujlwm lossis xav tau kev lim ntshav los ntawm 18 xyoo tom qab kuaj mob qog noj ntshav thawj zaug. Lawv muaj cuaj npaug siab dua lawv cov kwv tij uas tsis muaj mob qog noj ntshav (Oeffinger li al. 2006). Chemotherapy-induced AKI yog tus cwj pwm los ntawm ntau lub xeev pathological xws li podocytopathy, mob tubular raug mob, thiab siv lead ua nephropathy (Perazella 2012). Txawm hais tias AKI rov zoo, kho tsis zoo, thiab rov raug mob ntau zaus tuaj yeem ua rau tubulointerstitial fibrosis thiab glomerulosclerosis uas ua rau CKD (Venkatachalam li al. 2015; Basile li al. 2016), peb qhov kev tshawb pom qhia tias cov kws kho mob yuav tau saib xyuas me ntsis AKIs. Cov neeg mob qog noj ntshav feem ntau tau kawm ntau yam kev kho mob, uas tuaj yeem ua rau mob raum rov qab thiab muaj kev pheej hmoo ntawm CKD. Yog li, oncologists ua ke nrog nephrologists yuav tsum ua tib zoo xyuas txawm tias mob AKI thaum siv tshuaj khomob.

Cistanche tuaj yeem txhim kho lub raum ua haujlwm

Hauv kev kawm tam sim no, thaum 75 chav kawm, AKI tau kuaj pom hauv 58 chav kawm los ntawm CysC-based eGFR (77 feem pua) thiab 49 chav kawm los ntawm Cr-based eGFR (65 feem pua). Ntawm cov xwm txheej no, kev kuaj mob ntawm AKI tau pom zoo pom zoo siv ob qhov kev ntsuas ntsuas hauv 42 chav kawm. Los ntawm qhov sib txawv, muaj qhov sib txawv ntawm qhov tshwm sim ntawm AKI kuaj pom los ntawm CysC-based eGFR thiab Cr-based eGFR hauv 23 chav kawm, txawm hais tias tsis muaj qhov sib txawv tseem ceeb hauv qhov xwm txheej ntawm AKI tsis hais seb CysC-based eGFR lossis Cr-based eGFR. tau siv rau kev kuaj mob (p=0.104). Peb hais kom cov txheej txheem hauv qab no ua rau muaj qhov tsis sib xws: Ntawm xya qhov kev kawm kuaj mob AKI nkaus xwb los ntawm Cr-based eGFR, rau tus neeg mob (86 feem pua) tau txais asparaginase tam sim ua ntej kev txhim kho AKI. Txij li thaum asparaginase tuaj yeem txo cov ntshav CysC los ntawm kev txo qis cov ntshav triiodothyronine, uas txhawb nqa CysC tso tawm ntawm cov leeg nqaij los ntawm kev hloov pauv kev loj hlob-beta 1, AKI soj ntsuam siv CysC-based eGFR yuav raug saib xyuas vim qhov txo qis hauv cov ntshav CysC hauv cov neeg mob tau txais asparaginase ( Ferster et al. 1992; Kotajima et al. 2010). Lub caij no, ntawm 16 chav kawm kuaj mob AKI los ntawm kev siv CysC-based eGFR ib leeg, feem ntau muaj tus qhab nia Z tsis zoo rau lub cev qhov hnyav, qhia tias lawv tau txo cov leeg nqaij. Txij li cov ntshav Cr qib feem ntau cuam tshuam los ntawm cov leeg nqaij, qhov no yuav ua rau muaj qhov tsis zoo-tsis zoo hauv kev kuaj mob ntawm AKI tso siab rau Cr-based eGFR. Qhov tseem ceeb, Rayar et al. (2013) tau tshaj tawm tias cov menyuam yaus uas muaj TAG NRHO muaj cov leeg pob txha qis (txhais tau tias Z tus qhab nia ntawm −0.18) dua li cov menyuam noj qab haus huv thaum lub sijhawm kuaj mob.

Fig. 2. Tus nqi ntawm CysC-based eGFR thiab Cr-based eGFR txo qis thaum cov kws khomob kho mob nrog mob raum raug mob (AKI). Qhov nruab nrab txo tus nqi ntawm CysC-raws li eGFR (khoom khov kab) thiab Cr-based eGFR (dashed kab) txij li thaum pib ntawm chemotherapy ntawm 42 chav kawm nrog AKI tau qhia. Cov kab kab rov tav nyob rau hauv lub thawv sawv cev rau qhov nruab nrab qhov tseem ceeb, thiab hauv qab thiab sab saum toj ntawm lub thawv sawv cev rau 25th thiab 75th feem pua, feem. Cov kab ntsug txuas ntxiv los ntawm lub thawv rau 5 thiab 95 feem pua. AKI,mob raum raug mob; Cr, creatinine; CysC, cystatin C; eGFR, kwv yees glomerular filtration rate.

Serum Cr feem ntau yog siv rau hauv kev kuaj mob ntawm AKI thiab saib xyuas lub raum ua haujlwm. Txawm li cas los xij, nws cov qib yuav tsis hloov mus txog thaum kwv yees li 50 feem pua ​​​​ntawm lub raum ua haujlwm tau ploj lawm (Nguyen thiab Devarajan 2008). CysC yog cov protein tsawg molecular-yuag tas li tsim thiab zais los ntawm cov hlwb nucleated thoob plaws lub cev. Nws yog lim dej dawb los ntawm lub glomerulus thiab tag nrho reabsorbed thiab metab olized los ntawm lub raum proximal tubules; nws muaj qhov sib cuam tshuam nrog GFR raws li ntsuas siv cov xov tooj cua isotopes (Coll li al. 2000). Vim tias cov yam ntxwv lom neeg no, CysC tuaj yeem tsim nyog rau kev soj ntsuam ntawm lub raum ua haujlwm hauv cov menyuam yaus (Lankisch li al. 2006; Nakhjavan-Shahraki et al. 2017). Kev tshuaj ntsuam meta tsis ntev los no tau pom qhov zoo tshaj ntawm CysC tshaj Cr hauv kev kuaj mob AKI (Nakhjavan-Shahraki li al. 2017), uas nthuav tawm lwm txoj hauv kev rau kev kuaj mob ib txwm muaj hauv nephrology. Txawm li cas los xij, kev tswj hwm glucocorticoid hauv cov neeg laus uas muaj mob hawb pob thiab cov qog nqaij hlav tuaj yeem ua rau cov ntshav CysC nce siab ntawm lub raum ua haujlwm, txawm tias qhov tseeb mechanism tseem tsis paub (Bjarnadottir li al. 1995; Manetti li al. 2005). Qhov no tuaj yeem ua rau muaj qhov tsis tseeb ntawm AKI yog kev soj ntsuam los ntawm CysC-based eGFR. Hauv qhov sib piv, muaj kev sib cav txog seb glucocorticoids puas cuam tshuam rau cov ntshav CysC hauv cov neeg mob menyuam yaus (Bokenkamp li al. 2002; Foster et al. 2006; Bokenkamp et al. 2007; Bardi et al. 2010; Slort et al. 2010). Yog li, hauv txoj kev tshawb fawb tam sim no, qhov tshwm sim ntawm AKI tau muab sib piv los ntawm kev kho mob glucocorticoid. Cov txiaj ntsig tau pom tsis muaj qhov sib txawv tseem ceeb ntawm ob txoj kev tswj hwm ntawm AKI: qhov qub yog 77.4 feem pua, thaum tom kawg yog 77.3 feem pua ​​(Table 3). Tsis tas li ntawd, cov kev hloov pauv nyob rau hauv tus nqi ntawm CysC-raws li eGFR txo qis thaum 42 chav kawm ntawm AKI, uas suav nrog 28 chav kawm nrog glucocorticoids, tau pom kev txhim kho lub raum ua haujlwm tsis pub dhau 12 hnub txawm hais tias kev tswj hwm glucocorticoids txuas ntxiv 2 lub lis piam. Ua ke, peb ntseeg tias glucocorticoids muaj qhov cuam tshuam tsis zoo rau cov ntshav CysC qib thiab CysC-based eGFR thiab cov txiaj ntsig ntawm peb txoj kev tshawb fawb qhia tias CysC-based eGFR yog qhov rhiab dua li Cr-based eGFR rau kev ntsuas lub raum ua haujlwm hauv cov neeg mob TAG NRHO / LBL. Peb kuj tau sib piv AKI qhov xwm txheej los ntawm hom kev kho tshuaj khomob. AKI feem ntau tshwm sim thaum cov chav kawm sib sau ua ke, tej zaum yog vim kev siv cov tshuaj methotrexate siab. Txawm hais tias tsis yog qhov tseem ceeb, hauv txhua plaub hom kev kawm, AKI tau kuaj pom ntau dua thaum txhais tau tias siv CysC-based eGFR piv rau Cr-based eGFR, uas qhia tau hais tias muaj txiaj ntsig ntawm CysC-based eGFR hauv kev kuaj mob AKI thaum siv tshuaj khomob.

Txawm hais tias ob qho tib si CysC- thiab Cr-based eGFR muaj qhov zoo thiab qhov tsis zoo, peb pom tias muaj txiaj ntsig zoo hauv CysC-based eGFR dhau Cr-based eGFR rau kev kuaj mob ntxov ntawm AKI hauv cov neeg mob menyuam yaus nrog ALL / LBL tab tom siv tshuaj khomob. Tshawb xyuas AKI thaum ntxov yuav tso cai rau kev tiv thaiv tsim nyog los tiv thaiv lub raum tsis zoo ntxiv. Muaj peev xwm tiv thaiv kev kho mob nrog rau kev txo cov tshuaj noj, haus dej, kev tswj hwm cov tshuaj diuretics (Horie li al. 2018) thiab lwm yam tshuaj tiv thaiv raum yuav pab tiv thaiv CKD yav tom ntej. Hauv txoj kev tshawb no, peb tau ua raws li cov neeg mob rau qhov nruab nrab ntawm 29 lub hlis tom qab rov ua cov kev kawm kom paub meej txog kev txhim kho ntawm CKD; tsis muaj cov neeg mob tau txo eGFR. Txij li cov neeg mob uas tau ntsib AKI muaj kev pheej hmoo ntawm CKD yav tom ntej, peb yuav txuas ntxiv mus ntxiv.

Txoj kev tshawb no muaj qee qhov kev txwv uas yuav tsum tau xav txog. Ua ntej, raws li tag nrho cov kev tshawb fawb cov neeg mob tau zoo lawm, tsis muaj kev cuam tshuam los ntawm AKI. Cov kev tshawb fawb ntxiv yog xav tau los txiav txim seb qhov kev rov qab tuaj yeem ua kom nrawm nrog kev cuam tshuam, xws li txo koob tshuaj tiv thaiv kab mob, cov kua dej ntau ntau, lossis alkalization. Ntxiv mus, cov kev tshawb fawb yav tom ntej yuav tsum tau txiav txim siab seb qhov kev cuam tshuam thaum ntxov tuaj yeem txo qhov kev pheej hmoo ntawm kev loj hlob ntawm CKD. Qhov thib ob, cov tshuaj los ntawm cov kev kho mob yav dhau los yuav muaj qhov cuam tshuam rau cov kev kawm tom ntej. Txawm li cas los xij, vim tias qhov nruab nrab CysC-based eGFR thaum pib ntawm txhua chav kho mob yog 160 (IQR, 135 txog 181), peb ntseeg tias qhov muaj peev xwm no tsawg heev. Thib peb, tus qauv loj me me. Txawm li cas los xij, tus qauv loj txaus rau kev ntsuam xyuas thawj qhov tshwm sim ntawm lub sijhawm rau kev kuaj mob AKI. Cov nyhuv loj hauv peb txoj kev tshawb fawb yog 0.609, uas yog txaus rau cov ntaub ntawv tsis yog parametric. Cov qauv me me txwv tsis pub muaj kev tshawb fawb ntxiv txog qhov cuam tshuam ntawm tus kheej cov txheej txheem kho lossis tshuaj. Cov kev tshawb fawb ntxaws ntxiv nrog cov neeg mob ntau dua yog tsim nyog.

Hauv kev xaus, cov txiaj ntsig ntawm peb txoj kev tshawb fawb tau hais txog ob qho tseem ceeb ntsig txog AKI hauv cov neeg mob uas tau txais tshuaj kho mob rau menyuam yaus ALL / LBL. Ua ntej, peb tau qhia txog qhov muaj peev xwm ntawm AKI siab ntawm cov neeg mob. Txawm hais tias nephrotoxicity paub zoo nrog kev siv tshuaj khomob siv qee cov tshuaj tshwj xeeb, tsis muaj daim ntawv tshaj tawm tam sim no tau ntsuas nephrotoxicity vim ALL / LBL kev kho mob hauv menyuam yaus. Kev soj ntsuam tsis tu ncua ua rau peb tshawb pom txawm tias mob AKI. Qhov thib ob, CysC-raws li eGFR tso cai kuaj pom ua ntej ntawm AKI dua li Cr-based eGFR. Yog li ntawd, xav txog qhov zoo thiab qhov tsis zoo ntawm CysC-based eGFR thiab Cr-based eGFR hauv kev kuaj mob me nyuam yaus AKI thaum siv tshuaj khomob, peb xav kom nquag ua haujlwm rau lub raum los ntawm ob qho kev ntsuas.

Cistanche tuaj yeem tonify raum

Kev lees paub

Peb xav ua tsaug rau Editage (https://www.editage. com) rau kev kho lus Askiv.

Sau Kev Pab Txhawb

SA, ST thiab KK tsim kev kawm; TY, SA, thiab YA tau sau cov ntaub ntawv; TY, SA, YA thiab SY txheeb xyuas cov ntaub ntawv; TY, SA, MR thiab YA tau sau cov ntawv sau; thiab SY, TO, TK thiab ST tau muab kev txhawb nqa thiab tshuaj xyuas cov ntawv sau. KK saib xyuas tag nrho cov txheej txheem kawm. Txhua tus kws sau ntawv tau nyeem thiab pom zoo cov ntawv sau kawg.

Tsis sib haum xeeb

Cov kws sau ntawv tshaj tawm tsis muaj kev sib cav txog kev txaus siab.

Cov ntaub ntawv

Akcan-Arikan, A., Zappitelli, M., Loftis, LL, Washburn, KK, Jefferson, LS & Goldstein, SL (2007) Hloov kho RIFLE cov qauv hauv cov me nyuam mob hnyav nrog mob raum raug mob. Raum Int, 71, 1028-1035.

Bardi, E., Dobos, E., Kappelmayer, J. & Kiss, C. (2010) Kev sib txawv ntawm corticosteroids ntawm cov ntshav cystatin C hauv thrombocytopenic purpura thiab leukemia. Pathol. Oncol. Res., 16, 453-456.

Basile, DP, Bonventre, JV, Mehta, R., Nangaku, M., Unwin, R., Rosner, MH, Kellum, JA & Ronco, C.; ADQI XIII Ua Haujlwm Pab Pawg (2016) Kev nce qib tom qab AKI: nkag siab txog cov txheej txheem kho tsis zoo los kwv yees thiab txheeb xyuas cov kev kho mob. J. Am. Soc. Nephrol., 27, 687-697.

Bjarnadottir, M., Grubb, A. & Olafsson, I. (1995) Txhawb kev sib kho, dexamethasone-induced nce hauv cystatin C ntau lawm los ntawm HeLa hlwb. Luam theej duab. J. Clin. Lab. Invest., 55, 617-623.

Bokenkamp, ​​A., Laarman, CA, Braam, KI, van Wijk, JA, Kors, WA, Kool, M., de Valk, J., Bouman, AA, Spreeuwenberg, MD & Stoffel-Wagner, B. (2007) Cov txiaj ntsig ntawm kev kho corticosteroid rau qis-molecular yuag protein cov cim ntawm lub raum ua haujlwm. Clin. Cheem., 53, 2219-2221.

Bokenkamp, ​​A., van Wijk, JA, Lentze, MJ & Stoffel-Wagner, B. (2002) Cov nyhuv ntawm kev kho corticosteroid ntawm cov ntshav cystatin C thiab beta2-microglobulin concentrations. Clin. Chem., 48, 1123-1126.

Ciarimboli, G., Holle, SK, Vollenbrocker, B., Hagos, Y., Reuter, S., Burckhardt, G., Bierer, S., Herrmann, E., Pavenstadt, H., Rossi, R., Kleta , R. & Schlatter, E. (2011) New clues for nephrotoxicity induced by ifosfamide: preferential renal uptake through the human organic cation transporter 2. Mol. Pharm., 8, 270-279.

Cimerman, N., Brguljan, PM, Krasovec, M., Suskovic, S. & Kos, J. (2000) Serum cystatin C, ib tug muaj zog inhibitor ntawm cysteine ​​proteinases, yog elevated nyob rau hauv cov neeg mob hawb pob. Clin. Chim. Acta, 300, 83-95.

Cohen, J. (1992) Lub hwj chim primer. Psychol. Ib., 112, 155-159. Coll, E., Botey, A., Alvarez, L., Poch, E., Quinto, L., Saurina, A., Vera, M., Piera, C. & Darnell, A. (2000) Serum cystatin C raws li tus cim tshiab rau kev kwv yees tsis muaj kev cuam tshuam ntawm glomerular pom tus nqi thiab ua tus cim rau lub raum tsis zoo thaum ntxov. Am. J. Raum Dis., 36, 29-34.

Faul, F., Erdfelder, E., Lang, AG & Buchner, A. (2007) G*Power 3: ib qho kev hloov pauv ntawm kev txheeb xyuas lub zog rau kev sib raug zoo, kev coj cwj pwm, thiab biomedical sciences. Behav. Res. Methods, 39, 175-191.

Ferster, A., Glinoer, D., Van Vliet, G. & Otten, J. (1992) Thyroid function thaum lub sij hawm L-asparaginase kho rau cov me nyuam uas mob lymphoblastic leukemia: qhov sib txawv ntawm induction thiab lig intensification. Am. J. Pediatr. Hematol. Oncol., 14, 192-196.

Fisher, BT, Zaoutis, TE, Leckerman, KH, Localio, R. & Aplenc, R. (2010) Kev pheej hmoo rau lub raum tsis ua haujlwm hauv cov menyuam yaus uas mob ntshav qab zib mellitus: kev tshawb fawb rov qab. Pediatr. Ntshav Qab Zib, 55, 655-661.

Foster, J., Reisman, W., Lepage, N. & Filler, G. (2006) Kev cuam tshuam ntawm cov tshuaj nquag siv rau qhov tseeb ntawm cystatin C-derived glomerular filtration rate. Pediatr. Nephrol., 21, 235-238.

Horie, S., Oya, M., Nangaku, M., Yasuda, Y., Komatsu, Y., Yanagita, M., Kitagawa, Y., Kuwano, H., Nishiyama, H., Ishioka, C., Takaishi, H., Shimodaira, H., Mogi, A., Ando, ​​Y., Matsumoto, K., et al. (2018) Cov lus qhia rau kev kho mob raum raug mob thaum mob qog noj ntshav 2016. Clin. Exp. Nephrol., 22, 210-244.

Isojima, T., Kato, N., Ito, Y., Kanzaki, S. & Murata, M. (2016) Kev loj hlob tus qauv kab kos rau cov menyuam yaus Nyij Pooj nrog qhov nruab nrab thiab tus qauv sib txawv (SD) qhov tseem ceeb raws li xyoo 2000 daim ntawv ntsuam xyuas hauv tebchaws. Clin. Pediatr. Endocrinol., 25, 71-76.

Kellum, JA & Lameire, N.; KDIGO AKI Guideline Work Group (2013) Kev kuaj mob, kev ntsuam xyuas, thiab kev tswj cov mob raum raug mob: KDIGO cov ntsiab lus (Part 1). Crit. Ib., 17, 204.

Kab mob raum: Txhim kho Cov txiaj ntsig thoob ntiaj teb (KDIGO) CKD Ua Haujlwm Pab Pawg (2013) KDIGO 2012 cov lus qhia kev kho mob rau kev soj ntsuam thiab tswj cov kab mob raum ntev. Lub raum Inter. Suppl., 3, 1-150.

Ko, S., Venkatesan, S., Nand, K., Levidiotis, V., Nelson, C. & Janus, E. (2018) International statistical classification of disease and related health problems coding underestimates incidence and prevalence of mob raum. raug mob thiab mob raum mob nyob rau hauv cov neeg mob kev kho mob. Intern. Med. J., 48, 310-315.

Kooijmans, EC, Bokenkamp, ​​A., Tjahjadi, NS, Tettero, JM, van Dulmen-den Broeder, E., van der Pal, HJ & Veening, MA (2019) Cov tsos mob tshwm sim ntxov thiab lig tom qab kev kho mob nephrotoxic rau menyuam yaus mob qog noj ntshav. Cochrane Database Syst. Rev., 3, CD008944.

Kotajima, N., Yanagawa, Y., Aoki, T., Tsunekawa, K., Morimura, T., Ogiwara, T., Nara, M. & Murakami, M. (2010) Kev cuam tshuam ntawm cov thyroid hormones thiab hloov pauv kev loj hlob. -beta1 ntawm cystatin C concentrations. J. Int. Med. Res., 38, 1365-1373 ib. Lahoti, A., Kantarjian, H., Salahudeen, AK, Ravandi, F., Cortes, JE, Faderl, S., O'Brien, S., Wierda, W. & Mattiuzzi, GN (2010) Kev kwv yees thiab qhov tshwm sim ntawm mob raum raug mob hauv cov neeg mob uas mob myelogenous leukemia lossis muaj kev pheej hmoo siab myelodysplastic syndrome. Cancer, 116, 4063-4068.

Lankisch, P., Wessalowski, R., Maisonneuve, P., Haghgu, M., Hermsen, D. & Kramm, CM (2006) Serum cystatin C yog lub cim tsim nyog rau kev saib xyuas lub raum ua haujlwm hauv cov neeg mob qog noj ntshav, tshwj xeeb tshaj yog ntawm cov hluas heev. Pediatr. Ntshav Cancer, 46, 767-772.

Laterza, OF, Nqe, CP & Scott, MG (2002) Cystatin C: qhov kev kwv yees zoo dua ntawm glomerular pom tus nqi? Clin. Chem., 48, 699-707. Manetti, L., Genovesi, M., Pardini, E., Grasso, L., Lupi, I., Linda Morselli, L., Pellegrini, G. & Martino, E. (2005) Thaum ntxov tshwm sim ntawm methylprednisolone infusion ntawm cov ntshav cystatin C hauv cov neeg mob hnyav Graves 'ophthalmopathy. Clin. Chim. Acta, 356, 227-228.

McMahon, KR, Harel-Sterling, M., Pizzi, M., Huynh, L., Hessey, E. & Zappitelli, M. (2018) Kev soj ntsuam lub raum mus sij hawm ntev ntawm cov menyuam yaus kho nrog cisplatin, carboplatin, lossis ifosfamide : kev kawm pilot. Pediatr. Nephrol., 33, 2311-2320.

Meersch, M., Schmidt, C., Hoffmeier, A., Van Aken, H., Wempe, C., Gerss, J. & Zarbock, A. (2017) Tiv thaiv kev phais mob plawv-koom nrog AKI los ntawm kev siv KDIGO cov lus qhia Hauv cov neeg mob muaj kev pheej hmoo siab txheeb xyuas los ntawm biomarkers: PrevAKI randomized tswj kev sim. Intensive Care Med., 43, 1551-1561.

Nakamura, N., Watanabe, H., Okamura, K. & Kagami, S. (2018) Kev soj ntsuam ntawm lub raum kev ua haujlwm hauv cov menyuam yaus Nyij Pooj uas muaj cov kab mob malignancies siv cov tshuaj cystatin CJ Med. Kev nqis peev., 65, 231-235.

Nakhjavan-Shahraki, B., Yousefifard, M., Atei, N., Baikpour, M., Atei, F., Bazargani, B., Abbasi, A., Ghelichkhani, P., Javidilarijani, F. & Hosseini, M. . (2017) Qhov tseeb ntawm cystatin C hauv kev kwv yees ntawm mob raum raug mob hauv cov menyuam yaus; ntshav ntshav lossis zis ntau ntau: qhov twg ua haujlwm zoo dua? Kev tshuaj xyuas qhov systematic thiab metaanalysis. BMC Nephrol., 18, 120.

Nguyen, MT & Devarajan, P. (2008) Biomarkers rau kev tshawb pom ntxov ntawm lub raum raug mob. Pediatr. Nephrol., 23, 2151- 2157.

Oeffinger, KC, Mertens, AC, Sklar, CA, Kawashima, T., Hudson, MM, Meadows, AT, Friedman, DL, Marina, N., Hobbie, W., Kadan-Lottick, NS, Schwartz, CL, Leisenring , W. & Robison, LL; Childhood Cancer Survivor Study Group (2006) Kev noj qab haus huv nyob rau hauv cov neeg laus muaj txoj sia nyob ntawm kev mob qog noj ntshav thaum yau. N. Engl. J. Med., 355, 1572-1582.

Pabla, N. & Dong, Z. (2008) Cisplatin nephrotoxicity: mechanisms thiab renoprotective strategies. Raum Int., 73, 994-1007.

Perazella, MA (1999) Crystal-induced mob raum tsis ua haujlwm. Am. J. Med., 106, 459-465. Perazella, MA (2012) Onco-nephrology: lub raum toxicities ntawm chemotherapeutic agents. Clin. J. Am. Soc. Nephrol., 7, 1713- 1721.

Rayar, M., Webber, CE, Nayiager, T., Sala, A. & Barr, RD (2013) Sarcopenia nyob rau hauv cov me nyuam uas mob lymphoblastic leukemia. J. Pediatr. Hematol. Oncol., 35, 98-102.

Sethi, SK, Kumar, M., Sharma, R., Bazaz, S. & Kher, V. (2015) Mob raum raug mob nyob rau hauv cov me nyuam tom qab cardiopulmonary bypass: muaj feem yuav tshwm sim thiab tshwm sim. Indian Pediatr., 52, 223-226.

Slort, PR, Ozden, N., Pape, L., Offner, G., Tromp, WF, Wilhelm, AJ & Bokenkamp, ​​A. (2012) Sib piv cystatin C thiab creatinine hauv kev kuaj mob ntawm cov menyuam yaus lub raum tsis ua haujlwm. Pediatr. Nephrol., 27, 843-849.

Sutherland, SM, Byrnes, JJ, Kothari, M., Longhurst, CA, Dutta, S., Garcia, P. & Goldstein, SL (2015) AKI hauv tsev kho mob cov menyuam yaus: piv cov pRIFLE, AKIN, thiab KDIGO cov lus txhais. Clin. J. Am. Soc. Nephrol., 10, 554-561.

Uemura, O., Nagai, T., Ishikura, K., Ito, S., Hataya, H., Gotoh, Y., Fujita, N., Akioka, Y., Kaneko, T. & Honda, M. ( 2014a) Creatinine-based sib npaug los kwv yees qhov glomerular filtration rate hauv Nyiv cov menyuam yaus thiab cov tub ntxhais hluas uas muaj kab mob raum. Clin. Exp. Nephrol., 18, 626-633.

Uemura, O., Nagai, T., Ishikura, K., Ito, S., Hataya, H., Gotoh, Y., Fujita, N., Akioka, Y., Kaneko, T. & Honda, M. ( 2014b) Cystatin C-raws li kev sib npaug rau kev kwv yees glomerular pom tus nqi hauv Nyiv cov menyuam yaus thiab cov tub ntxhais hluas. Clin. Exp. Nephrol., 18, 718-725.

Venkatachalam, MA, Weinberg, JM, Kriz, W. & Bidani, AK (2015) Failed tubule recovery, AKI-CKD transition, thiab mob raum. J. Am. Soc. Nephrol., 26, 1765- 1776.

Yong, Z., Pei, X., Zhu, B., Yuan, H. & Zhao, W. (2017) Predictive value of serum cystatin C rau mob raum raug mob rau cov neeg laus: ib tug meta-kev soj ntsuam ntawm lub prospective cohort trials. Sci. Ib., 7, 41012.